Adverse Event Clinical Research R4 Backport, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-ae-research-backport-ig/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
Generated Narrative: MedicationRequest
Resource MedicationRequest "medicationrequest-for-bresentrik"
identifier: http://www.bmc.nl/portal/medstatements
/1234568900-studyDrug (use: official)
status: active
intent: order
medication: Medication/bresentrik: bresentrik 2mg tablet
subject: Patient/JanetPatient: Janet " CLINICAL TRIAL PATIENT"
supportingInformation: ResearchStudy/BreastCancerTrial
authoredOn: 2023-04-05
requester: : Could be reference to inline contained profile such as Reference(practitioner-1) Ronald Bone, MD
reasonCode: Breast Cancer (SNOMED CT#254837009)
instantiatesCanonical: http://baseUrlOfHospitalHolding/PlanDefinition/protocol-for-the-ResearchStudy
dosageInstruction
sequence: 1
text: 6 mg PO daily for remission induction; adjust dosage to white blood cell (WBC) count. With hold treatment if WBC is less than 15,000/µL; resume when WBC is greater than 50,000/µL
timing: Once per 1 days
route: Oral route (qualifier value) (SNOMED CT#26643006)
doseAndRate
dispenseRequest
numberOfRepeatsAllowed: 1
quantity: 600 mg (Details: UCUM code mg = 'mg')
ExpectedSupplyDurations
Value Unit System Code 30 days Unified Code for Units of Measure (UCUM) d